The proceedings follow a PIL seeking a ban on sale of weight loss drugs that are still undergoing clinical trials internationally. The court asked DCGI to submit report within 3 months.
Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved in select countries by means of local clinical trials waiver.
Underlining need for more accountability, experts also stress that govt data does not include fixed dose combination drugs, which account for over 40% of drugs sold in India.
Drugs Controller General of India, who heads CDSCO, says Entod pharma failed to reply satisfactorily to queries raised. Entod to challenge suspension of approval.
All India Ophthalmological Society has set up expert group to review PresVu & develop guidelines on side-effects, keeping in mind 'potential inappropriate marketing, indiscriminate use'.
Launched Tuesday by Entod Pharmaceuticals under brand name PresVu, eye drop will treat presbyopia, an age-related condition causing blurry vision. To be available across India by October.
In an executive order, the DGCI has specified a list of countries under rule 101 of New Drugs and Clinical Trials Rules, 2019. List includes US, UK & EU, among others.
Therapy developed by IIT-Bombay spin-off company ImmunoACT approved for relapsed-refractory B-cell lymphoma, leukemia, to be available in around 20 govt & pvt hospitals across major cities.
Panel report notes that oral phenylephrine is no better than placebo for relieving nasal congestion. In India, phenylephrine is widely used in cough and cold medicines.
Project follows outcry over NMC rule, now on hold, asking medical practitioners to prescribe generics or face penalty. Dr Cyriac Abby Philips or ‘@TheLiverDoc’ part of project.
With bad loans shrinking & capital buffers stronger, urban co-op banks’ new umbrella body NUCFDC is now prioritising rollout of digital transformation.
Amidst a doctrinal shift towards joint theaterisation and greater synergy between the various wings of the forces, the Indian Army in 2025 moved further on its path to Vision@2047.
Many of you might think I got something so wrong in National Interest pieces written this year. I might disagree! But some deserve a Mea Culpa. I’d deal with the most recent this week.
COMMENTS